Telehealth program for advance care planning in older adults with myeloid malignancies
Official title: A Telehealth Advance Care Planning Intervention for Older Patients With Myeloid Malignancies: A Pilot Randomized Controlled Trial
Run by University of Rochester · NCT05875805 · Data updated 2026-11-12
This study tests if a telehealth program that helps older adults with blood cancers talk about their serious illness and make healthcare plans can reduce their anxiety and improve communication with doctors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 60 Years and up |
| Sex | All |
| Enrollment | 207 (estimated) |
| Sponsor | University of Rochester Academic / other |
| Locations | 1 site (Rochester, New York) |
| Status | Recruiting |
| Started | May 20, 2024 |
| Main results expected | September 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | September 11, 2026 |
| Trial ID | NCT05875805 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are older adults aged 60 and above with a diagnosis of acute myeloid leukemia, myelodysplastic syndromes, or similar myeloid malignancies.
✕Probably not a fit
Patients who are younger than 60 or do not have a diagnosis of myeloid malignancies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to evaluate the effectiveness of a telehealth-delivered Serious Illness Care Program designed to improve healthcare communication and reduce anxiety among older patients with myeloid malignancies. The program includes structured conversations between patients and healthcare providers, focusing on serious illness discussions and completion of advance directives. The study will compare the telehealth intervention to an education control group to assess its preliminary efficacy. Participants will include older adults diagnosed with conditions such as acute myeloid leukemia and myelodysplastic syndromes.
Why it matters
Potential benefit: If successful, this program could enhance communication about serious illness and improve patients' emotional well-being while ensuring their healthcare preferences are documented.
How similar studies have gone: Previous studies have shown success with similar telehealth interventions for serious illness conversations, indicating potential for positive outcomes in this population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion and Exclusion Criteria for Patients Inclusion criteria: * Age ≥60 years * A diagnosis of AML, MDS, and similar myeloid malignancies (including but not limited to MDS/MPN overlap syndrome, myelofibrosis) * Being managed in the outpatient settings * Able to provide informed consent * English-speaking Exclusion criteria: \- None Inclusion and Exclusion Criteria for Caregivers Inclusion criteria: * Age ≥18 years * Selected by patient when asked if there is a "family member, partner, friend, or caregiver with whom you discuss or who can be helpful in health-related matters" * Able to provide informed consent * English-speaking Exclusion criteria: \- None Inclusion and Exclusion Criteria for Oncology Providers Inclusion criteria: \- Oncologists and/or APPs who will be conducting the telehealth-delivered ACP visit Exclusion criteria: \- None
Where it's running
-
University of Rochester
Rochester, New York, United States Recruiting
Study contacts
- Principal investigator: Kah Poh Loh — University of Rochester
- Study coordinator: Kah Poh Loh, MD
- Email: Kahpoh_Loh@URMC.Rochester.edu
- Phone: 585-276-4353
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating GLB-001 for patients with myeloid malignancies
This study is testing a new oral treatment called GLB-001 to see if it is safe and effective for people with certain types of blood cancers that have come back or didn't respond to other treatments.
-
Using hyperbaric oxygen therapy with stem cell transplants
This study is testing whether hyperbaric oxygen therapy can help patients with chronic leukemias and myelofibrosis who are getting stem cell transplants feel better and recover more effectively.
-
CD33-armed immune cell treatment for adults with MRD-positive AML or MDS
This treatment will try giving adults with MRD-positive AML or MDS infusions of their own T cells coated with a CD33-directed bispecific antibody together with standard hypomethylating therapy (and possibly venetoclax) to see if it is safe and lowers residual disease.
-
Adding decitabine and venetoclax to fludarabine/melphalan reduced‑intensity transplant for myeloid cancers
This study tests whether giving decitabine and venetoclax around a reduced‑intensity allogeneic transplant is safe for adults with high‑risk acute myeloid leukemia or myelodysplastic syndromes.
-
Using Tranexamic Acid to Prevent Bleeding in Blood Cancer Patients
This study is testing if tranexamic acid can help prevent bleeding in patients with blood cancers like myelodysplastic syndromes and acute myeloid leukemia.
-
GTB-3650 treatment for high-risk myeloid malignancies
This study is testing a new treatment called GTB-3650 to see if it can help adults with tough-to-treat blood cancers like acute myeloid leukemia feel better and respond to therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.